Stay updated with breaking news from Cll Sll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.
Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).
Catherine C. Coombs, MD, presents data investigating venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia.